Financial Contrast: SOPHiA GENETICS (NASDAQ:SOPH) versus Poseida Therapeutics (NASDAQ:PSTX)

SOPHiA GENETICS (NASDAQ:SOPHGet Rating) and Poseida Therapeutics (NASDAQ:PSTXGet Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability and analyst recommendations.

Insider and Institutional Ownership

31.0% of SOPHiA GENETICS shares are held by institutional investors. Comparatively, 46.7% of Poseida Therapeutics shares are held by institutional investors. 4.9% of SOPHiA GENETICS shares are held by company insiders. Comparatively, 29.2% of Poseida Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation & Earnings

This table compares SOPHiA GENETICS and Poseida Therapeutics’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
SOPHiA GENETICS $40.45 million 4.68 -$73.68 million ($1.48) -2.02
Poseida Therapeutics $31.24 million 20.00 -$124.97 million ($0.68) -10.69

SOPHiA GENETICS has higher revenue and earnings than Poseida Therapeutics. Poseida Therapeutics is trading at a lower price-to-earnings ratio than SOPHiA GENETICS, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and target prices for SOPHiA GENETICS and Poseida Therapeutics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SOPHiA GENETICS 0 1 2 0 2.67
Poseida Therapeutics 0 0 4 0 3.00

SOPHiA GENETICS currently has a consensus price target of $6.67, suggesting a potential upside of 122.97%. Poseida Therapeutics has a consensus price target of $16.00, suggesting a potential upside of 120.08%. Given SOPHiA GENETICS’s higher possible upside, equities analysts plainly believe SOPHiA GENETICS is more favorable than Poseida Therapeutics.

Profitability

This table compares SOPHiA GENETICS and Poseida Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
SOPHiA GENETICS -210.25% -39.47% -33.12%
Poseida Therapeutics -19.26% -21.56% -10.59%

Risk and Volatility

SOPHiA GENETICS has a beta of 0.34, meaning that its share price is 66% less volatile than the S&P 500. Comparatively, Poseida Therapeutics has a beta of 0.12, meaning that its share price is 88% less volatile than the S&P 500.

Summary

Poseida Therapeutics beats SOPHiA GENETICS on 9 of the 13 factors compared between the two stocks.

About SOPHiA GENETICS

(Get Rating)

SOPHiA GENETICS SA operates as a healthcare technology company. The company offers SOPHiA DDM platform, a cloud-based software-as-a-service platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, products, and services are used by hospital, laboratory, and biopharma worldwide. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Saint-Sulpice, Switzerland.

About Poseida Therapeutics

(Get Rating)

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, ovarian, and other epithelial-derived cancers. In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma. Further, it is developing P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC. Additionally, the company engages in the development of P-OTC-101 and P-FVIII-101 that are clinical stage liver-directed gene therapies; and other allogeneic dual CAR candidates. It has a research collaboration and license agreement with Takeda Pharmaceutical Company Limited. The company was incorporated in 2014 and is headquartered in San Diego, California.

Receive News & Ratings for SOPHiA GENETICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SOPHiA GENETICS and related companies with MarketBeat.com's FREE daily email newsletter.